Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species
Gabriele Bianco(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Cristina Costa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Rossana Cavallo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paolo Gaibani(University of Verona), Matteo Boattini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Comini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
European Journal of Clinical Microbiology & Infectious Diseases
January 19, 2024
Cited by 25
Related Papers
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
|Antibiotics|2022|117
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
|BMC Infectious Diseases|2021|70
Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy
|Clinical Microbiology and Infection|2018|60
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
|European Journal of Clinical Microbiology & Infectious Diseases|2021|51